Dry powders of metal-containing compounds

• US 20030180378A1
• Filed: 10/22/2002
• Published: 09/25/2003
• Est. Priority Date: 07/27/2000
• Status: Active Grant

• Current Assignee: NUCRYST Pharmaceuticals Corp. (The Westaim Corporation)
• Original Assignee: NUCRYST Pharmaceuticals Corp. (The Westaim Corporation)
• Inventors: Gillis, Scott H., Schechter, Paul, Burrell, Robert E.
• Granted Patent: US 6,989,157 B2
• Time in Patent Office: Days
• US Class Current: 424/618
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 2800/413 Nanosized, i.e. having sizes below 100 nm
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/242 Gold; Compounds thereof
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 33/38 Silver; Compounds thereof
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61K 8/19 containing inorganic ingredients
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0078 for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• CPC Class Codes: A61K 9/14 Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
• CPC Class Codes: A61K 9/1682 Processes
• CPC Class Codes: A61K 9/51 Nanocapsules; Nanoparticles; nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61K 9/7023 : Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61L 15/44 : Medicaments
• CPC Class Codes: A61L 15/46 : Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
• CPC Class Codes: A61L 17/145 : Coating
• CPC Class Codes: A61L 2300/102 : Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
• CPC Class Codes: A61L 2300/104 : Silver, e.g. silver sulfadiazine
• CPC Class Codes: A61L 2300/404 : Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/606 : Coatings
• CPC Class Codes: A61L 2300/624 : Nanocapsules
• CPC Class Codes: A61L 2300/63 : Crystals
• CPC Class Codes: A61L 27/30 : Inorganic materials
• CPC Class Codes: A61L 29/10 : Inorganic materials
• CPC Class Codes: A61L 29/16 : Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/082 : Inorganic materials
• CPC Class Codes: A61L 31/16 : Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61Q 17/005 : Antimicrobial preparations
• CPC Class Codes: A61Q 19/00 : Preparations for care of the skin
• CPC Class Codes: B82Y 5/00 : Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Dry powders of metal-containing compounds are disclosed. Methods of preparing and using the dry powders, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.

Claims

1. A method of treating a subject having a condition, comprising:

contacting an area of the subject having the condition with a nanocrystalline metal-containing compound by injecting a free-standing powder of the nanocrystalline metal-containing compound into the subject.

2. The method of claim 1, wherein the metal-containing compound is selected from the group consisting of metals and alloys.

3. The method of claim 1, wherein the metal-containing compound is selected from the group consisting of metal oxides, metal nitrides, metal borides, metal halides and metal hydrides.

4. The method of claim 1, wherein the metal-containing compound comprises a metal selected from the group consisting of silver, gold, platinum and palladium.

5. The method of claim 1, wherein the metal-containing compound comprises silver.

6. The method of claim 1, wherein the metal-containing compound comprises an ionic compound.

7. The method of claim 1, wherein the metal-containing compound comprises atoms, molecules or clusters.

8. The method of claim 1, wherein the metal-containing compound comprises an atomically disordered, crystalline compound.

9. The method of claim 1, wherein the metal-containing compound comprises an antimicrobial compound.

10. The method of claim 1, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

11. The method of claim 1, wherein the condition is selected from skin conditions and integument conditions.

12. The method of claim 11, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

13. The method of claim 11, wherein the condition is selected from the group consisting of a burn, eczema, erythroderma, an insect bite, mycosis fungoides, pyoderma gangrenosum, eythrema multiforme, rosacea, onychomyocosis, acne, psoriasis, Reiter'"'"'s syndrome, pityriasis rubra pilaris, hyperpigmentation, vitiligo, hypertropic scarring, keloid, lichen plainus, age related skin disorders and hyperproliferative variants of the disorders of keratinization.

14. The method of claim 1, wherein the condition comprises a respiratory condition.

15. The method of claim 14, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

16. The method of claim 14, wherein the respiratory condition is selected from the group consisting of lupus pneumonitis, asthma, emphysema, bronchitis, pulmonary edema, acute respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary fibrosis, pulmonary atelectasis, tuberculosis, pneumonia, sinusitis, pharyngitis, mucositis, chronic obstructive pulmonary disease, bronchiectasis, and cystic fibrosis.

17. The method of claim 1, wherein the condition comprises a musculo-skeletal condition.

18. The method of claim 17, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

19. The method of claim 17, wherein the musculo-skeletal condition is selected from the group consisting of tendonitis, osteomyelitis, fibromyalgia, bursitis and arthritis.

20. The method of claim 1, wherein the condition comprises a circulatory condition.

21. The method of claim 20, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

22. The method of claim 20, wherein the circulatory condition is selected from the group consisting of arteriosclerosis, septicemia, leukemia, ischemic vascular disease, lymphangitis and atherosclerosis.

23. The method of claim 1, wherein the condition comprises cancer.

24. The method of claim 23, wherein the cancer is selected from the group consisting of tumors and hematologic malignancies.

25. The method of claim 1, wherein the area of the subject is selected from the group consisting of a hyperplastic tissue, a tumor tissue and a cancerous lesion.

26. The method of claim 25, wherein the method induces apoptosis at the area of the subject.

27. The method of claim 25, wherein the method modulates matrix metalloproteinases at the area of the subject.

28. The method of claim 1, wherein the condition is selected from mucosal conditions and serosal conditions.

29. The method of claim 28, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

30. The method of claim 28, wherein the condition is selected from the group consisting of pericarditis, Bowen'"'"'s disease, prostatitis, sinusitis, digestive disorders, toxic epidermal necrolysis syndrome, Stevens Johnson syndrome, cystic fibrosis, bronchitis, pneumonia, pharyngitis, common cold, ear infections, sore throat, sexually transmitted diseases, inflammatory bowel disease, colitis, hemorrhoids, thrush, dental conditions, oral conditions, conjunctivitis, and periodontal conditions.

31. The method of claim 1, wherein the free-standing powder is injected with a needleless injector.

32. The method of claim 1, wherein the free-standing powder has an average particle size of about two microns or less.

33. A method of treating a subject having a condition, comprising:

contacting an area of the subject having the condition with a nanocrystalline metal-containing compound by inhaling a free-standing powder of the nanocrystalline metal-containing compound.

34. The method of claim 33, wherein the nanocrystalline metal-containing compound is selected from the group consisting of metals and alloys.

35. The method of claim 33, wherein the nanocrystalline metal-containing compound is selected from the group consisting of metal oxides, metal nitrides, metal borides, metal halides and metal hydrides.

36. The method of claim 33, wherein the nanocrystalline metal-containing compound comprises a metal selected from the group consisting of silver, gold, platinum and palladium.

37. The method of claim 33, wherein the nanocrystalline metal-containing compound comprises silver.

38. The method of claim 33, wherein the nanocrystalline metal-containing compound comprises an ionic compound.

39. The method of claim 33, wherein the nanocrystalline metal-containing compound comprises atoms, molecules or clusters.

40. The method of claim 33, wherein the nanocrystalline metal-containing compound comprises an atomically disordered, crystalline compound.

41. The method of claim 33, wherein the nanocrystalline metal-containing compound comprises an antimicrobial compound.

42. The method of claim 33, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

43. The method of claim 33, wherein the condition is selected from skin conditions and integument conditions.

44. The method of claim 43, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

45. The method of claim 43, wherein the condition is selected from the group consisting of a burn, eczema, erythroderma, an insect bite, mycosis fungoides, pyoderma gangrenosum, eythrema multiforme, rosacea, onychomyocosis, acne, psoriasis, Reiter'"'"'s syndrome, pityriasis rubra pilaris, hyperpigmentation, vitiligo, hypertropic scarring, keloid, lichen plainus, age related skin disorders and hyperproliferative variants of the disorders of keratinization.

46. The method of claim 33, wherein the condition comprises a respiratory condition.

47. The method of claim 46, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

48. The method of claim 46, wherein the respiratory condition is selected from the group consisting of lupus pneumonitis, asthma, emphysema, bronchitis, pulmonary edema, acute respiratory distress syndrome, bronchopulmonary dysplasia, pulmonary fibrosis, pulmonary atelectasis, tuberculosis, pneumonia, sinusitis, pharyngitis, mucositis, chronic obstructive pulmonary disease, bronchiectasis, and cystic fibrosis.

49. The method of claim 33, wherein the condition comprises a musculo-skeletal condition.

50. The method of claim 49, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

51. The method of claim 49, wherein the musculo-skeletal condition is selected from the group consisting of tendonitis, osteomyelitis, fibromyalgia, bursitis and arthritis.

52. The method of claim 33, wherein the condition comprises a circulatory condition.

53. The method of claim 52, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

54. The method of claim 52, wherein the circulatory condition is selected from the group consisting of arteriosclerosis, septicemia, leukemia, ischemic vascular disease, lymphangitis and atherosclerosis.

55. The method of claim 33, wherein the condition comprises cancer.

56. The method of claim 55, wherein the cancer is selected from the group consisting of tumors and hematologic malignancies.

57. The method of claim 33, wherein the area of the subject is selected from the group consisting of a hyperplastic tissue, a tumor tissue and a cancerous lesion.

58. The method of claim 57, wherein the method induces apoptosis at the area of the subject.

59. The method of claim 57, wherein the method modulates matrix metalloproteinases at the area of the subject.

60. The method of claim 33, wherein the condition is selected from mucosal is conditions and serosal conditions.

61. The method of claim 60, wherein the condition is selected from the group consisting of bacterial conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, noncancerous growths and cancerous conditions.

62. The method of claim 60, wherein the condition is selected from the group consisting of pericarditis, Bowen'"'"'s disease, prostatitis, sinusitis, digestive disorders, toxic epidermal necrolysis syndrome, Stevens Johnson syndrome, cystic fibrosis, bronchitis, pneumonia, pharyngitis, common cold, ear infections, sore throat, sexually transmitted diseases, inflammatory bowel disease, colitis, hemorrhoids, thrush, dental conditions, oral conditions, conjunctivitis, and periodontal conditions.

63. The method of claim 33, wherein the free-standing powder is inhaled with a dry powder inhaler.

64. The method of claim 33, wherein the free-standing powder has an average particle size of about two microns or less.

65. A method of treating a subject having a condition, comprising:

contacting an area of the subject having the condition with a nanocrystalline metal-containing compound by inhaling a free-standing powder of the nanocrystalline metal-containing compound.

66. The method of claim 65, wherein the nanocrystalline metal-containing compound is selected from the group consisting of metals and alloys.

67. The method of claim 65, wherein the nanocrystalline metal-containing compound is selected from the group consisting of metal oxides, metal nitrides, metal borides, metal halides and metal hydrides.

68. The method of claim 65, wherein the nanocrystalline metal-containing compound comprises a metal selected from the group consisting of silver, gold, platinum and palladium.

69. The method of claim 65, wherein the nanocrystalline metal-containing compound comprises silver.

70. The method of claim 65, wherein the nanocrystalline metal-containing compound comprises an ionic compound.

71. The method of claim 65, wherein the nanocrystalline metal-containing compound comprises atoms, molecules or clusters.

72. The method of claim 65, wherein the nanocrystalline metal-containing compound comprises an antimicrobial compound.